Research Progress on the Abnormal Expression of Galectin-3 and p16 in Cervical Cancer
Despite the increasing awareness of early diagnosis and treatment has brought about a downtrend in the morbidity and mortality of cervical cancer, recent years have still witnessed an obvious uptrend in the incidence rate among the young patients. Galectin-3 and p16, which play an important role in the incidence and development of cervical cancer and are closely related to its diagnosis and prognosis, are often used as important indicators of the clinical diagnosis of cervical cancer. This article reviews the protein structures of galectin-3 and p16 as well as their expression mechanism and abnormal expression regarding to cervical cancer.
Lim AW, Ramirez AJ, Hamilton W, et al., 2014, Delays in Diagnosis of Young Females with Symptomatic Cervical Cancer in England: An Interview-based Study. Br J Gen Pract, 64:e602–10. DOI: 10.3399/bjgp14x681757.
National Health and Family Planning Commission of the People’s Republic of China, 2013, Gongjingai ji Aiqianbingbian Guifanhua Zhenliao Zhinan (shixing) [Guidelines for Standardized Diagnosis and Treatment of Cervical Cancer and Precancerous Lesions (for Trial Implementation)]. Chin J Front Med Sci, 5:37–46. Available from: http://www.yixueqianyan.cn/CN/abstract/abstract721.shtml.
Farhad M, Rolig AS, Redmond WL, 2018, The Role of Galectin-3 in Modulating Tumor Growth and Immunosuppression within the Tumor Microenvironment. Oncoimmunology, 7:e1434467.
DOI: 10.1080/2162402x.2018.1434467.
Punt S, Thijssen VL, Vrolijk J, et al., 2015, Galectin-1,-3 and-9 Expression and Clinical Significance in Squamous Cervical Cancer. PLoS One, 10:e0129119. DOI: 10.1371/journal.pone.0129119.
Fu QH, Zhang Y, Fu Y, 2016, Relationship between Galectin-3 Gene Polymorphism and Susceptibility and Prognosis of Cervical Cancer. Chin J Clin Oncol Rehabil, 23:1062–4. Available from: https://www.cnki.net/kcms/doi/10.13455/j.cnki.cjcor.2016.09.10.html.
Fang SQ, Feng YM, Li M, 2017, Correlations of Galectin-3 Gene Polymorphisms with Risk and Prognosis of Cervical Cancer in Chinese Populations: A Case-Control Study. Oncol Res Treat, 40:533–9. DOI: 10.1159/000475502.
Wang LY, Zhao YY, Wang YS, et al., 2018, The Role of Galectins in Cervical Cancer Biology and Progression. BioMed Res Int, 2018:1–11.
Yang C, Zhang YJ, Chen HY, et al., 2013, Galectin 3 Promotes Cervical Cancer Metastasis. J Trop Med, 13:851–4. Available from: http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_rdyxzz201307017.
Nie L, 2011, The Expression of Galectin-3 in Different Cervix Lesion and its Relation with the Load of High-risk Human Papillomavirus, dissertation, Dalian Medical University. Available from: http://www.d.wanfangdata.com.cn/thesis/Y2028315.
Zhao SL, Pan BC, Fu X, et al., 2016, Galectin 3 and VEGF Expression Level and the Research of Cervical Cancer. J Rare Uncommon Dis, 23:55–7. Available from: http://d.wanfangdata.com.cn/periodical/hsjbzz201604022.
Liu X, Lu YB, Yang XL, 2011, Expression and Significance of Galectin-3 in Cervical Lesions. J Kunming Med Coll, 32:69–72.
Ma YH, He XY, Jing J, et al., 2012, Clinical Significance of Fascin and Galectin-3 Expression in Cervical Cancer. J Diagn Pathol, 19:366–9.
Chen LJ, Zhai MJ, 2019, Correlation between the Levels of Galectin-3 and CA19-9 in Cervical Cancer Tissues and Clinicopathological Features. Matern Child Health Care China, 34:5298–301. Available from: https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFD&filename=ZFYB201922075.
Li M, Feng YM, Fang SQ, 2017, Overexpression of Ezrin and Galectin-3 as Predictors of Poor Prognosis of Cervical Cancer. Braz J Med Biol Res, 50:e5356. DOI: 10.1590/1414-431x20165356.
Liu X, 2010, Study on Galectin-3 and Serum VEGF Expression in Cervical Cancer and Its Correlation, dissertation, Kunming Medical College.
Li T, Zhu JF, Mao YY, et al., 2018, Expression and Clinical Significance of Galectin-3 and Programmed Death Receptor-1 in Cervical Squamous Cell Carcinoma. Prog Mod Biomed, 18:3529–32. Available from: https://www.cnki.net/kcms/doi/10.13241/j.cnki.pmb.2018.18.029.html.
Tang Y, He L, Li YB, 2016, Expression and Significance of Galectin-3 in CIN and Cervical Squamous Cell Carcinoma. J Guzhou Med Univ, 41:967–70. Available from: https://www.cnki.net/kcms/doi/10.19367/j.cnki.1000-2707.2016.08.025.html.
Wu HG, Ren LS, Zhang X, et al., 2014, Expressions and Clinical Significances of CD44v6 and Galectin-3 in Cervical Carcinoma. Sichuan Med J, 35:966–9. Available from: https://d.wanfangdata.com.cn/periodical/scyx201408016.
He XY, 2013, Annexin A7 and Galectin-3 Expression in Cervical Cancer and its Relationship with Lymphatic Metastasis. thesis, Lanzhou University.
Xu MR, Wang XJ, Zhang SL, et al., 2014, Expression and Significance of Galectin-3 and VEGF in Cervical Lesions. J Nanchang Univ Med Sci, 54:13–17. https://d.wanfangdata.com.cn/periodical/ChlQZX
Jpb2RpY2FsQ0hJTmV3UzIwMjEwMTI1EhBqeHl4
eXhiMjAxNDAzMDA1GghkZmcxdTV1eA%3D%3D
Wu HG, Yuan SF, Zhou KM, et al., 2015, The Expression of β-Catenin and Galectin-3 in Cervical Carcinoma and Its Clinical Pathological Significances. West China Med J, 30:1452-6. DOI: 10.7507/1002-0179.20150416.
Lv JY, Zhuang GL, Lu BY, 2009, Galectin-3, MMP-2 Danbai zai Zigongneimoaixianai Zhong de Biaoda ji Linchuangyiyi [The Expression and Clinical Significance of Galectin-3 and MMP-2 Protein in Endometrioid Adenocarcinoma]. Heilongjiang Med Pharm, 32:41–2. DOI: 10.3969/j.issn.1008-0104.2009.06.010
Dietlmeier S, Ye Y, Kuhn C, et al., 2020, The Prostaglandin Receptor EP2 Determines Prognosis in EP3-negative and Galectin-3-high Cervical Cancer Cases. Sci Rep, 10:1154. DOI: 10.1038/s41598-020-58095-3.
Li M, Zhu JH, 2019, Gongjingai Zuzhizhong Galectin-3 de Biaodayiyi [The Significance of Galectin-3 Expression in Cervical Cancer]. Pop Sci, 5:195. Available from: http://www.cnki.com.cn/Article/CJFDTotal-KXDH201905177.htm.
Liu J, Cheng Y, He M, et al., 2014, Vascular Endothelial Growth Factor C Enhances Cervical Cancer Cell Invasiveness via Upregulation of Galectin-3 Protein. Gynecol Endocrinol, 30:461–5. DOI: 10.3109/09513590.2014.898054.
Chen CC, Huang LW, Bai CH, et al., 2016, Predictive Value of p16/Ki-67 Immunocytochemistry for Triage of Women with Abnormal Papanicolaou Test in Cervical Cancer Screening: A Systematic Review and Meta-analysis. Ann Saudi Med, 36:245–51. DOI: 10.5144/0256-4947.2016.245.
Fu HC, Chuang IC, Yang YC, et al., 2018, Low P16INK4A Expression Associated with High Expression of Cancer Stem Cell Markers Predicts Poor Prognosis in Cervical Cancer after Radiotherapy. Int J Mol Sci, 19:2541. DOI: 10.3390/ijms19092541.
Silva DC, Gonçalves AK, Cobucci RN, et al. Immunohistochemical Expression of p16, Ki-67 and p53 in Cervical Lesions a Systematic Review. Pathol Res Pract, 213:723–9. DOI: 10.1016/j.prp.2017.03.003.
Zhai RF, Guo JJ, Xu XY, et al., 2019, DNA Beiti Gaoweixing HPVki67 p16 zai Gongjinglinai Huanzhe Zhuanyi Yinxing Pengqiang Linbajie Zhong de Jiance yiyi [Detection and significance of DNA ploidy high-risk HPV ki67 p16 in cervical squamous cell carcinoma patients with negative metastatic pelvic lymph nodes]. Chin Remedies Clin, 19:2194–6. Available from: http://www.cnki.com.cn/Article/CJFDTotal-YWLC201913026.htm.
Zhou CP, Zhang P, Zhou LL, et al., 2018, Expression and Clinical Significance of P16INK4A and KISS-1 in Cervical Cancer. Chin J Woman Child Health Res, 29:1556–9. DOI: 10.3969/j.issn.1673-5293.2018.12.013.
Shang LN, Zhou ZY, Zhang C, et al., 2019, Expression of Bcl2 Inhibitor of Transcription 1 and E-cadherin in Different Regions of Cervical Squamous Cell Carcinoma and their Relationship with Expression of P16INK4a. Acad J Second Military Med Univ, 40:1317–24. Available from: http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_dejydxxb201912006.
Eleutério J Jr., Lima TS, Cunha MD, et al., 2017, Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. Rev Bras Ginecol Obstet, 39:21–5. DOI: 10.1055/s-0037-1598042.
Li DF, Luo AH, Luo BT, et al., 2020, Vimentin, ER, CEA, PR yiji P16 zai Zigongneimoyangxianai yu Gongjingxianai Zhong de Biaoda Yanjiu ji Chayixing Fenxi [Vimentin, ER, CEA, PR and p16 Expression in Endometrioid Adenocarcinoma and Cervical Adenocarcinoma and Their Differences Analysis]. Renowned Doctor, 5:7–8. Available from: https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CJFD&filename=MGYI202005004.
Wang X, Chen P, Liao YH, 2019, p16, p53, PR, Vim zai Yuanfagongjingxianai Zhong de Biaoda ji Linchuangyiyi [The Expression and Clinical Significance of p16, p53, PR and Vim in Primary Cervical Adenocarcinoma]. J Math Med, 32:1782–3. Available from: http://www.cnki.com.cn/Article/CJFDTotal-SLYY201912021.htm.
Nicolás I, Saco A, Barnadas E, et al., 2020, Prognostic Implications of Genotyping and p16 Immunostaining in HPV-Positive Tumors of the Uterine Cervix. Mod Pathol, 33:128–37. DOI: 10.1038/s41379-019-0360-3.
Stiasny A, Freier CP, Kuhn C, et al., 2017, The Involvement of E6, p53, p16, MDM2 and Gal-3 in the Clinical Outcome of Patients with Cervical Cancer. Oncol Lett, 14:4467–76. DOI: 10.3892/ol.2017.6752.